Ameriprise
VERV

Ameriprise’s Verve Therapeutics VERV Stock Holding History

Ameriprise’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-103,955
Closed -$1.17M – 4191
2025
Q2 		$1.17M Buy
103,955
+57,507
+124% +$328K ﹤0.01% 3198
2025
Q1 		$212K Sell
46,448
-212,425
-82% -$1.42M ﹤0.01% 3772
2024
Q4 		$1.46M Buy
258,873
+32,817
+15% +$185K ﹤0.01% 3074
2024
Q3 		$1.09M Buy
226,056
+46,638
+26% +$271K ﹤0.01% 3187
2024
Q2 		$876K Buy
179,418
+79,458
+79% +$499K ﹤0.01% 3202
2024
Q1 		$1.33M Sell
99,960
-3,713
-4% -$49.2K ﹤0.01% 3052
2023
Q4 		$1.45M Buy
103,673
+41,643
+67% +$516K ﹤0.01% 3032
2023
Q3 		$823K Buy
62,030
+14,008
+29% +$226K ﹤0.01% 3227
2023
Q2 		$900K Sell
48,022
-9,038
-16% -$151K ﹤0.01% 3217
2023
Q1 		$823K Buy
57,060
+15,766
+38% +$309K ﹤0.01% 3238
2022
Q4 		$799K Sell
41,294
-2,315
-5% -$61.3K ﹤0.01% 3227
2022
Q3 		$1.5M Buy
43,609
+1,894
+5% +$60.4K ﹤0.01% 2915
2022
Q2 		$637K Buy
41,715
+10,462
+33% +$162K ﹤0.01% 3311
2022
Q1 		$713K Buy
31,253
+3,255
+12% +$93K ﹤0.01% 3343
2021
Q4 		$1.03M Sell
27,998
-610
-2% -$25.6K ﹤0.01% 3239
2021
Q3 		$1.34M Buy
28,608
+2,326
+9% +$137K ﹤0.01% 3033
2021
Q2 		$1.58M Buy
+26,282
New +$1.09M ﹤0.01% 3020

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Ameriprise's VERV Position: Q3 2025 in Review

Ameriprise sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 103,955 shares — an estimated $1.17M sold.

Ameriprise first reported a position in VERV in Q2 2021 and held it in 17 quarters. The position peaked at $1.58M in Q2 2021. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Ameriprise reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Ameriprise sold 103,955 Verve Therapeutics shares in Q3 2025, an estimated $1.17M.
  • Ameriprise first reported a position in Verve Therapeutics in Q2 2021 and held it in 17 quarters.
  • Ameriprise's Verve Therapeutics position peaked at $1.58M in Q2 2021.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Ameriprise's 13F filing for Q3 2025, filed 14 Nov 2025.